Fig. 1
From: Tolerance to the antinociceptive effects of chronic morphine requires c-Jun N-terminal kinase
Antinociceptive effect of SP600125 in the formalin test. SP600125 suppresses formalin-induced pain behavior (a) in a dose-dependent manner. The four different doses of SP600125 (0.1, 1, 3 and 10 mg/kg) decrease the area under the curve (AUC) of (b) Phase 1 and (c) Phase 2 pain behavior. Data are expressed as mean ± S.E.M. (n = 5–6 per group). *p < 0.0001 for SP600125 different doses vs. vehicle group (ANOVA); + p < 0.017 vs. SP600125 (0.1 mg/kg) group (ANOVA, Bonferroni post hoc); x p < 0.0001 vs. vehicle group (ANOVA); #p < 0.039 for SP600125 (3 mg/kg) vs. SP600125 (0.1 mg/kg) (ANOVA, Bonferroni post hoc); ^p < 0.048 for SP600125 (3 mg/kg) vs. SP600125 (0.1, 1 or 10 mg/kg) (ANOVA, Bonferroni post hoc)